Hematology

Around the Helix: Cell and Gene Therapy Company Updates – July 9, 2025

July 11th 2025

Review top news and interview highlights from the week ending July 11, 2025.

Optimal Use of CAR T-Cell Therapy, Bispecifics, and Other Novel Strategies Will Determine the Future of DLBCL Therapy

July 9th 2025

Alexey Danilov, MD, PhD, the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California

By Alexey Danilov, MD, PhD
Courtney Flaherty

July 6th 2025

CGTLive®’s Weekly Rewind – July 4, 2025

FDA Drops REMS Requirement for 6 Approved CAR T-Cell Therapies

July 4th 2025

FDA Approves Sanofi’s siRNA Therapy Fitusiran for the Treatment of Hemophilia A and B

July 3rd 2025

Latest CME Events & Activities

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Risk-Adapted Management of Multiple Myeloma—How Do the Experts Do It?

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Broadening Horizons in Newly Diagnosed Multiple Myeloma—Exploring New Combination Approaches and Their Impact

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

9th Annual Live Medical Crossfire®: Hematologic Malignancies

July 26, 2025

Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

New Horizons in Multiple Myeloma Treatment – Selection and Sequencing From Newly Diagnosed to Relapsed/Refractory Disease

Medical Crossfire®: Uncovering The Clinical Utility of Combination Therapies and MRD Assessment in Newly Diagnosed Multiple Myeloma

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Community Practice Connections™: 8th Annual School of Nursing Oncology™

SimulatEd™: Patient-Centered Care to Improve Outcomes in Chronic Lymphocytic Leukemia

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Innovations in MDS Care: Navigating New Treatment Paradigms, Breakthrough Therapies, and Emerging Clinical Evidence

Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

SimulatEd™ in Multiple Myeloma: Personalizing Care Plans to Treat Newly Diagnosed Patients

More News

CGTLive®’s Weekly Rewind – March 28, 2025

March 31st 2025

The product is marketed under the name Qfitlia.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

March 28th 2025

Review top news and interview highlights from the week ending March 28, 2025.

CGTLive®’s Weekly Rewind – March 21, 2025

March 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

March 21st 2025

Review top news and interview highlights from the week ending March 21, 2025.

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

March 20th 2025

The product is marketed under the name Amvuttra.

Shanxi Bethune Hospital Evaluating CAR-T for R/R Hematological Tumors in Phase 2/3 Clinical Trial

March 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – March 14, 2025

March 17th 2025

CGTLive® took a closer look at the single-center, open-label study, which aims to assess the safety and efficacy of the CAR-T therapy.

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

March 14th 2025

Review top news and interview highlights from the week ending March 14, 2025.

News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025

March 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – March 7, 2025

March 9th 2025

In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest news and expert insights in gene therapy for hemophilia, which is among the most common of these disorders.

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

March 7th 2025

Review top news and interview highlights from the week ending March 7, 2025.

FDA Activity Recap: February 2025 Features Multiple BLA Acceptances, RMAT Designations, and More

March 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive®’s Weekly Rewind – February 28, 2025

March 2nd 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

February 28th 2025

Review top news and interview highlights from the week ending February 28, 2025.

Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response

February 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Alfred L. Garfall, MD, MS, the associate professor of medicine (hematology-oncology) and director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at the Hospital of the University of Pennsylvania

Alfred L. Garfall, MD, MS;Noah Stansfield

February 26th 2025

Alfred L. Garfall, MD, MS, discussed data from the phase 2 BMT CTN 1902 trial.

Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,

Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response

Alfred L. Garfall, MD, MS;Jax DiEugenio

February 24th 2025

The director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at the Hospital of the University of Pennsylvania discussed data from the phase 2 BMT CTN 1902 trial.

CGTLive®’s Weekly Rewind – February 21, 2025

Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez

February 21st 2025

Review top news and interview highlights from the week ending February 21, 2025.

Evaluating Zamto-Cel in R/R DLBCL

February 21st 2025

The company made the decision based on a lack of interest from the patient and clinician communities.

Nirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin

Nirav N. Shah, MD;Noah Stansfield

February 20th 2025

Nirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin, discussed efficacy data presented at the 2025 Tandem Meetings.

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Evaluating Poseida Therapeutics' P-BCMA-ALLO1 With Optimized Lymphodepletion in R/R Myeloma

February 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center

Bhagirathbhai Dholaria, MBBS;Noah Stansfield

February 19th 2025

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed new results presented at Tandem 2025.

Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin

Nirav Shah, MD, MSHP, on Evaluating Zamto-Cel in R/R DLBCL

Nirav N. Shah, MD;Jax DiEugenio

February 18th 2025

The associate professor of medicine at Medical College of Wisconsin discussed efficacy data presented at the 2025 Tandem Meetings.

Galapagos’ HESPERIA Study Tracks Long-Term Follow-Up for Patients Treated With the Company’s CAR-T Therapies

Bhagirathbhai R. Dholaria, MD, on Evaluating P-BCMA-ALLO1 in R/R Myeloma

February 17th 2025

CGTLive® took a closer look at the phase 3 study, which is tracking patients for up to 15 years after their treatment with GLPG CAR-T products.

Bhagirathbhai Dholaria, MBBS;Jax DiEugenio

February 16th 2025

The associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center discussed results from a phase 1 clinical trial.

Keys to a Successful Cell and Gene Therapy Launch

Molly Borchardt, PharmD;Phil Cyr, MPH;Erin Lopata, PharmD, MPH;Jason Foster, MBA

February 16th 2025

The success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.

CGTLive®’s Weekly Rewind – February 14, 2025

No Significant Reduction of CRS or ICANS Seen With Sobi's Anakinra in Patient's Receiving Liso-Cel for LBCL

February 14th 2025

Review top news and interview highlights from the week ending February 14, 2025.

Jordyn Sava

February 14th 2025

The data, which comes from a phase 2 trial, were presented at the 2025 Tandem Meetings.

CareDx’s AlloHeme Shows Accuracy in Detecting Relapse Following AlloHSCT in AML and MDS

Phase 2 Trial for BMS's Liso-Cel Meets Primary End Point in R/R Marginal Zone Lymphoma Cohort

February 13th 2025

AlloHeme utilizes detection of increased mixed chimerism (iMC) at a threshold of 0.2% or greater in the recipient’s chimerism between 2 consecutive readings to predict relapse.